Jun 11, 2019 / 09:00PM GMT
Robert Patrick Jones - Goldman Sachs Group Inc., Research Division - VP
All right. Good afternoon, everybody. Welcome to the AmerisourceBergen session. I'm Bob Jones. I cover the health care supply chain here at Goldman Sachs, very excited to introduce AmerisourceBergen, as you know, a leading drug wholesaler and much more in the U.S. and globally. I'm joined by Steve Collis, Chairman, President and CEO of AmerisourceBergen; and Jim Cleary, EVP and CFO.
I think by this point, everyone knows the format. If you have a question, raise your hand. We'll get you a microphone. But otherwise, I think we're just going to jump right into Q&A.
Questions and Answers:
Robert Patrick Jones - Goldman Sachs Group Inc., Research Division - VPSteve, I think one of the biggest focuses for the industry quite frankly for the last several years but I think really coming out of this past quarter has been around, has the core pharma business stabilized and is, in fact, EBIT at the core level? I know there's always a lot of moving pieces. But just organically at the